



SPAFID CONNECT

Informazione Regolamentata n. 0957-52-2019	Data/Ora Ricezione 24 Settembre 2019 10:10:17	MTA
--	---	-----

Societa' : DiaSorin

Identificativo : 122879

Informazione
Regolamentata

Nome utilizzatore : DIASORINN02 - Fava

Tipologia : REGEM

Data/Ora Ricezione : 24 Settembre 2019 10:10:17

Data/Ora Inizio : 24 Settembre 2019 10:10:18

Diffusione presunta

Oggetto : DIASORIN LAUNCHES VZV DIRECT
MOLECULAR TEST IN EUROPE

Testo del comunicato

Vedi allegato.

DIASORIN LAUNCHES VZV DIRECT MOLECULAR TEST IN EUROPE

Saluggia - September 24, 2019 – DiaSorin (FTSE MIB: DIA) announced today that it has received CE marking for VZV Swab Direct assay. The new molecular diagnostic test enables the direct detection of varicella-zoster virus (VZV) DNA from both cutaneous and mucocutaneous swab specimens. The assay is used with the LIAISON MDX instrument and complements the company's HSV 1 & 2 Direct kit. DiaSorin Molecular has also submitted the VZV Swab assay to the FDA for 510(k) clearance.

Varicella-zoster virus infection causes two clinically distinct forms of disease, depending on whether an individual is experiencing a primary (chickenpox) or secondary (shingles) infection.

Chickenpox is a highly contagious disease that is usually contracted in early childhood. It can cause health complications especially in older individuals. After initial infection, VZV becomes latent in sensory nerve ganglia and can reactivate later in life to cause shingles (herpes zoster). This is a painful condition that can result in complications such as post-herpetic neuralgia and central nervous system infections.

Although several vaccines have been available since the 1990s, it is estimated that greater than 90% of the population will acquire the disease by the age of 15. The clinical presentation of zoster can often be confused with the dermal manifestation of HSV, which makes it important to detect VZV rapidly for proper patient treatment and management.

“We are committed to expanding our menu of high-quality assays that can be used with our LIAISON MDX platform,” said Michelle Tabb, Chief Scientific Officer at DiaSorin Molecular. “Customers are looking to consolidate the testing platforms in their labs. Our test menu including new assays like VZV, along with the workflow efficiencies we deliver, make our platform increasingly attractive and in demand.”

DiaSorin

Headquartered in Italy and listed in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field. For over 50 years, the Company has been developing, producing and marketing reagent kits for IVD worldwide.

The Group has a presence on the 5 continents with 25 companies, 5 foreign branches, 6 manufacturing facilities and 5 research centers throughout the world. Through constant investments in research and development, and using its own distinctive expertise in the field of immunodiagnosics to deliver a high level of innovation, DiaSorin offers today the broadest range of specialty tests available in the immunodiagnosics market and new tests in the molecular diagnostics markets, which identify DiaSorin Group as the “Diagnostic Specialist”.

For additional information, please contact:

Riccardo Fava

Corporate Vice President Communication & Investor Relations

Tel: +39.0161.487988

riccardo.fava@diasorin.it

Ines Di Terlizzi

Investor Relator

Tel: +39.0161.487567

ines.diterlizzi@diasorin.it

Fine Comunicato n.0957-52

Numero di Pagine: 3